What is the current Price Target for the Design Therapeutics Inc stock?

The average Design Therapeutics Inc target price is $21.42. This is 73.58% higher than the current stock price. The highest price target is 87.20%, the lowest is 63.70%. 8 Analysts have issued a price target Design Therapeutics Inc 2027 .

How high will the Design Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Design Therapeutics Inc stock will rise. The performance of stocks, including the Design Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Design Therapeutics Inc stock today?

The performance of Design Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Design Therapeutics Inc stock fall?

The decline in Design Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Design Therapeutics Inc Forecast, price target & analysts

$12.57

1.86%

Nasdaq, Oct 05, 01:51 pm EDT. Market open.

ISIN

US25056L1035

Symbol

DSGN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Analysts Charts Ownership News Strategies

Design Therapeutics Inc Target price 2026 - Analyst rating & recommendation

Design Therapeutics Inc Classifications & Recommendation

Buy

92%

Hold

Design Therapeutics Inc Price Target

Target Price	$21.42
Price	$12.34
Potential	73.58% register free of charge
Number of Estimates	8

	8 Analysts have issued a price target Design Therapeutics Inc 2027 . The average Design Therapeutics Inc target price is $21.42. This is 73.58% register free of charge higher than the current stock price. The highest price target is $23.10 87.20% register free of charge , the lowest is $20.20 63.70% register free of charge .
	A rating was issued by 13 analysts: 12 Analysts recommend Design Therapeutics Inc to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Design Therapeutics Inc stock has an average upside potential 2027 of 73.58% register free of charge . Most analysts recommend the Design Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '25	2026 Estimates
P/E		negative

9 Analysts have issued a Design Therapeutics Inc forecast for earnings per share. The average Design Therapeutics Inc EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2025. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2027	$-1.62 16.55% unlock
2028	$-2.00 23.46% unlock
2029	$-1.54 23.00% unlock
2030	$-0.05 96.75% unlock
2031	$1.69 3,480.00% unlock
2032	$3.63 114.79% unlock
2033	$5.07 39.67% unlock

Current	-10.92	86.16%
2026	-8.88 18.68% unlock
2027	-7.60 14.41% unlock
2028	-6.16 18.95% unlock
2029	-8.04 30.52% unlock
2030	-234.00 2,810.45% unlock
2031	7.31 103.12% unlock
2032	3.40 53.49% unlock
2033	2.44 28.24% unlock

Design Therapeutics Inc...

Current Design Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Wells Fargo	Locked ➜ Locked	Locked	Oct 02 2026
Oppenheimer	Locked ➜ Locked	Locked	May 04 2026
Jefferies	Locked ➜ Locked	Locked	Mar 16 2026
RBC Capital	Locked ➜ Locked	Locked	Mar 10 2026
Oppenheimer	Locked ➜ Locked	Locked	Jan 07 2026
Leerink Partners	Locked ➜ Locked	Locked	Dec 03 2025
RBC Capital	Locked ➜ Locked	Locked	Nov 20 2025

Analyst Rating	Date
Locked Wells Fargo: Locked ➜ Locked	Oct 02 2026
Locked Oppenheimer: Locked ➜ Locked	May 04 2026
Locked Jefferies: Locked ➜ Locked	Mar 16 2026
Locked RBC Capital: Locked ➜ Locked	Mar 10 2026
Locked Oppenheimer: Locked ➜ Locked	Jan 07 2026
Locked Leerink Partners: Locked ➜ Locked	Dec 03 2025
Locked RBC Capital: Locked ➜ Locked	Nov 20 2025

Discover more stocks with a high price target

NIO ADR 86.90%

Alibaba Group Holding Ltd 80.17%

Rheinmetall 66.50%

Tencent Holdings Ltd. 60.60%

Adyen 56.10%

Uber Technologies 51.26%

BYD 49.89%

TUI 46.72%

Infineon 45.44%

Siemens Energy 43.75%

Netflix 43.74%

Adidas 43.36%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now